API SUPPLIERS

API Suppliers

1

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

1

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Mirati Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

Details:

MRTX1133 is an investigational, highly potent, selective and reversible inhibitor of KRASG12D that is optimized to sustain near complete target inhibition. It is currently being investigated for KRASG12D-driven cancers.

Lead Product(s): MRTX1133

Therapeutic Area: Oncology Product Name: MRTX1133

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2023

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for MRTX1133

MRTX1133

MRTX1133

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

1 API Suppliers

1 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development